Business Wire

TX-BLUE-YONDER

1.8.2024 17:13:29 CEST | Business Wire | Press release

Share
Blue Yonder Acquires One Network Enterprises to Unlock an Agile, Interconnected Supply Chain Ecosystem

Blue Yonder, the leader in digital supply chain transformations, today announced the closing of its acquisition of One Network Enterprises (One Network) at an enterprise value of approximately $839 million. The acquisition gives Blue Yonder customers the ability to collaborate and share data – from inventory levels to raw and finished goods materials movement – in real time across all trading partners up and down the supply chain.

With increasing volatility and continuous disruptions, retailers, manufacturers and logistics service providers (LSPs) need to achieve multi-enterprise transparency with trading partners, unify plans and actions, and conduct business in real time in order to enable more accurate cross-functional decision-making and eliminate the time gap between order planning and fulfillment. It’s no longer sufficient for companies to rely on periodic updates about their inventory, capacity, and resources; true business agility requires real-time information across an entire network.

With the addition of One Network’s commercial technology, Blue Yonder can now offer customers a multi-enterprise, multi-tier network ecosystem; artificial intelligence (AI)-powered supply chain assistants to identify, monitor, analyze, and resolve problems; and a simplified process to onboard and work with trading partners. Real-time inventory and capacity views help customers match supply and demand, detect and resolve problems, and orchestrate resources across their network of trading partners. One Network will continue to independently service and provide tailored technology solutions to its government customers.

“One Network’s industry-leading commercial technology will seamlessly be integrated into the Blue Yonder Platform. Their supply chain network and intelligent control tower deliver superpowered insights to businesses looking to fortify their supply chains,” said Duncan Angove, CEO, Blue Yonder. “Our customers can boost visibility, agility and speed thanks to a single source of truth provided by the Blue Yonder Platform and the digital network, all enhanced by our AI assistants, solvers and predictions. This allows customers to see issues both downstream and upstream in real time, so they can avoid disruptions and make better decisions. From One Network’s capabilities to its forward-looking mission, the company perfectly embodies Blue Yonder’s vision to transform the supply chain.”

With this acquisition, Blue Yonder customers will be able to address volatility and disruptions in the market, plan with greater accuracy, meet rising customer expectations, and simplify complexity within their supply chains. Blue Yonder customers will have access to the following benefits:

  • Navigating increasing uncertainty and volatility with real-time visibility across multiple tiers to anticipate risks, assess scenarios, and instantly redirect resources where needed most to deliver the greatest impacts to their business and sustainability goals.
  • Optimizing of resources, from capacity and inventory to workforce and carriers to better serve their business customers, capitalize on new market opportunities, and accelerate revenue growth.
  • Collaborating and orchestrating of their supply chain in real-time across a global network of 150,000 (and counting) trading partners using a shared view and dataset that ensures planning objectives flow into execution and vice versa to optimize critical KPIs.

“Blue Yonder is building the supply chain of the future,” said Angove. “To succeed in today’s business environment, planning and logistics teams need to make decisions faster. They need to collaborate with more partners. They need faster responsiveness to disruptions. One Network’s multi-tier and multi-enterprise network has a large role to play here, and we’re proud to join forces with them to make a lasting difference.”

This acquisition also catalyzed Blue Yonder’s expanded presence in Dallas, where it has been hiring extensively to support its momentum. Blue Yonder is now designating Dallas as its Global Innovation Center. In May during its annual customer conference, ICON, Blue Yonder announced a new AI Innovation Studio in Dallas where the company is hosting design-led AI Agent workshops with customers. Blue Yonder also plans to add a state-of-the-art Customer Experience Center in Dallas where the company will showcase its latest innovations that are transforming complex global supply chains.

One Network is the third company Blue Yonder has acquired since Q4 2023, following Doddle in November 2023 and flexis AG in February. These deals mark approximately $1 billion in M&A investments and are emblematic of Blue Yonder’s intent to transform the global supply chain.

About Blue Yonder

Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling business to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your PotentialTM www.blueyonder.com

“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731317929/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye